Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 5,808 shares of the company's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $35.89, for a total transaction of $208,449.12. Following the transaction, the chief executive officer now owns 476,046 shares in the company, valued at approximately $17,085,290.94. The trade was a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Ying Du also recently made the following trade(s):
- On Friday, April 4th, Ying Du sold 2,945 shares of Zai Lab stock. The stock was sold at an average price of $33.11, for a total transaction of $97,508.95.
- On Monday, March 3rd, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $32.44, for a total value of $1,622,000.00.
- On Friday, February 28th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $34.47, for a total value of $1,723,500.00.
Zai Lab Price Performance
Shares of Zai Lab stock traded down $1.74 during trading hours on Tuesday, hitting $27.07. The company's stock had a trading volume of 2,122,402 shares, compared to its average volume of 791,899. The company has a market capitalization of $2.97 billion, a PE ratio of -9.77 and a beta of 1.09. The stock has a 50 day moving average of $32.76 and a 200 day moving average of $28.96. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $39.77.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). The business had revenue of $109.07 million during the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. Equities analysts expect that Zai Lab Limited will post -2.58 EPS for the current year.
Analyst Ratings Changes
ZLAB has been the topic of a number of recent analyst reports. Bank of America restated a "neutral" rating and set a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a report on Monday, March 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, March 13th. Scotiabank started coverage on shares of Zai Lab in a report on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price objective for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a report on Thursday, March 27th.
View Our Latest Analysis on ZLAB
Institutional Investors Weigh In On Zai Lab
Large investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its stake in Zai Lab by 3.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 121,084 shares of the company's stock worth $2,923,000 after purchasing an additional 3,860 shares during the period. PEAK6 Investments LLC bought a new stake in shares of Zai Lab in the third quarter valued at about $386,000. Erste Asset Management GmbH acquired a new position in shares of Zai Lab during the third quarter worth about $357,000. Janus Henderson Group PLC grew its holdings in shares of Zai Lab by 34.2% during the third quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company's stock worth $211,488,000 after buying an additional 2,232,507 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in Zai Lab in the 3rd quarter valued at approximately $325,000. Institutional investors own 41.65% of the company's stock.
About Zai Lab
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Featured Stories
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
